leadf
logo-loader
viewAnteris Technologies Ltd

Admedus directors increase shareholdings

au_admedus_manufacturing_facility_2_358_553867745e1da.jpg

Admedus (ASX:AHZ) directors have increased their respective investments in the company through participation in the fully subscribed $16.1 million 1 for 7 rights issue priced at $0.07 per share.

The rights issue is part of a broader $28.1 million capital raising that be used to increase sales of its lead regenerative tissue product CardioCel®.

Proceeds will also support continued development of the company’s regenerative tissue portfolio and advance its immunotherapy programs with Professor Ian Frazer.

Managing director Lee Rodne acquired 714,286 shares for $50,000.02, taking his direct interest up to 26,992,820 shares.

Executive director Michael Bennett subscribed for 80,000 shares for $5,600 while non-executive director Peter Turvey acquired 396,504 shares for $27,755.28.

Turvey now has a direct and indirect interest in 3,172,039 AHZ shares while Bennett has 11,674,000 shares.

Earlier this week, the company appointed Genpharm as its distributor in the Middle East and North Africa region.

This adds to its presence with CardioCel used in 31 centres in Europe, 31 centres in the U.S. as well as recent approvals for use in Canada and Hong Kong.

Over 1,200 patients have benefited from CardioCel® as part of their cardiovascular repair surgery.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Anteris Technologies Ltd

Price: 3.99 AUD

ASX:AVR
Market: ASX
Market Cap: $23.58 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read